Mundipharma said on September 27 that it has filed an application in Japan for its general anesthetic med Anerem 50 mg for IV Injection (remimazolam), seeking its use in the “sedation during the examinations and procedures in gastrointestinal endoscopy.” Anerem,…
To read the full story
Related Article
BUSINESS
- Astellas Cuts Costs Ahead of Schedule, Key Assets Entering Late Stages
February 5, 2026
- Astellas Lifts Full-Year Forecast, Drops 2 Pipeline Programs
February 5, 2026
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- MSA Drug NPC-29 Set to Enter PIII This Month: Nobelpharma CEO
February 5, 2026
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





